Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency.

Mismatch repair (MMR)-deficient cancers have been discovered to be highly responsive to immune therapies such as PD-1 checkpoint blockade, making their definition in patients, where they may be relatively rare, paramount for treatment decisions. In this study, we utilized patterns of mutagenesis known as mutational signatures, which are imprints of the mutagenic processes associated with MMR deficiency, to identify MMR-deficient breast tumors from a whole-genome sequencing dataset comprising a cohort of 640 patients. We identified 11 of 640 tumors as MMR deficient, but only 2 of 11 exhibited germline mutations in MMR genes or Lynch Syndrome. Two additional tumors had a substantially reduced proportion of mutations attributed to MMR deficiency, where the predominant mutational signatures were related to APOBEC enzymatic activity. Overall, 6 of 11 of the MMR-deficient cases in this cohort were confirmed genetically or epigenetically as having abrogation of MMR genes. However, IHC analysis of MMR-related proteins revealed all but one of 10 samples available for testing as MMR deficient. Thus, the mutational signatures more faithfully reported MMR deficiency than sequencing of MMR genes, because they represent a direct pathophysiologic readout of repair pathway abnormalities. As whole-genome sequencing continues to become more affordable, it could be used to expose individually abnormal tumors in tissue types where MMR deficiency has been rarely detected, but also rarely sought. Cancer Res; 77(18); 4755-62. ©2017 AACR.

[1]  T. Aparicio,et al.  PD-1 blockade in tumors with mismatch-repair deficiency , 2015 .

[2]  Aung Ko Win,et al.  Risk of breast cancer in Lynch syndrome: a systematic review , 2013, Breast Cancer Research.

[3]  M. Stratton,et al.  Deciphering Signatures of Mutational Processes Operative in Human Cancer , 2013, Cell reports.

[4]  M. Koike,et al.  Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer , 1997, Nature Genetics.

[5]  Christopher D. Heinen,et al.  Milestones of Lynch syndrome: 1895–2015 , 2015, Nature Reviews Cancer.

[6]  David C. Jones,et al.  Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.

[7]  Jay Shendure,et al.  Classification and characterization of microsatellite instability across 18 cancer types , 2016, Nature Medicine.

[8]  M. Loda,et al.  Instability-High Tumor Unmethylated Allele in the Resulting Microsatellite Normal Tissue and Loss of Heterozygosity of the Gene in MLH 1 Associated with Hypermethylation of the A Hereditary Nonpolyposis Colorectal Carcinoma Case , 2002 .

[9]  J. Saurin,et al.  Novel biallelic mutations in MSH6 and PMS2 genes: gene conversion as a likely cause of PMS2 gene inactivation , 2007, Human mutation.

[10]  Kenric Leung,et al.  The Life History of 21 Breast Cancers , 2015, Cell.

[11]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[12]  Serena Nik-Zainal,et al.  Mechanisms underlying mutational signatures in human cancers , 2014, Nature Reviews Genetics.

[13]  L. Diaz,et al.  Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. , 2016, The oncologist.

[14]  E. Kuipers,et al.  Somatic aberrations of mismatch repair genes as a cause of microsatellite‐unstable cancers , 2014, The Journal of pathology.

[15]  R. Fleischmann,et al.  Mutations of two P/WS homologues in hereditary nonpolyposis colon cancer , 1994, Nature.

[16]  Robin J. Leach,et al.  Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer , 1993, Cell.

[17]  K. Kinzler,et al.  Mismatch repair deficiency in phenotypically normal human cells , 1995, Science.

[18]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[19]  K. Kinzler,et al.  The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints , 2015, Journal of Immunotherapy for Cancer.

[20]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[21]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[22]  Joshy George,et al.  Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.

[23]  R. Fleischmann,et al.  Mutation of a mutL homolog in hereditary colon cancer. , 1994, Science.

[24]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[25]  Bert Vogelstein,et al.  Hypermutability and mismatch repair deficiency in RER+ tumor cells , 1993, Cell.

[26]  D. Ward,et al.  Mutation in the DNA mismatch repair gene homologue hMLH 1 is associated with hereditary non-polyposis colon cancer , 1994, Nature.

[27]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[28]  E. Birney,et al.  HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures , 2017, Nature Medicine.

[29]  James R. Eshleman,et al.  Microsatellite Instability as a Biomarker for PD-1 Blockade , 2016, Clinical Cancer Research.